Promising new data on lutetium-177 PSMA radioligand therapy

Posted on July 2, 2018 by Sitemaster

According to a presentation given last week in San Francisco, lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy has significant clinical activity in men with metastatic prostate cancer (as opposed to just in men with very late stages of prostate cancer). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 11 Comments »

Yet another new PMSA-linked radioisotope enters clinical trials in prostate cancer

Posted on October 12, 2016 by Sitemaster

As many readers will be aware, there has been a lot of ongoing research using the gallium-68 (68Ga) radioisotope linked to various forms of prostate-specific membrane antigen (PSMA) in concert with PET scan imaging to identify sites of early recurrence of prostate cancer. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: , , , , , | 7 Comments »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives